Blogs

How a biotech IR advisor can help you target generalists and strengthen your capital markets strategy.

A practical look at the strategic and operational questions biotech companies should be asking well before pursuing an IPO.

After a bullish JPMorgan Healthcare Conference, investor interest in biotech is returning. Here are practical ways management teams can maximize their IR calendars by working smarter and selectively expanding availability.

From signs of a durable biotech rally to capital markets discipline, here are our biotech IR advisors' takeaways from the JPMorgan Healthcare Conference.

Discover how to “stake your claim” while staying positive

Good Communication Builds Respect, Poor Communication Impairs Credibility

Generalist investors are re-engaging with biotech as the market strengthens. Here's how to stand out to these important investors

Cultivating strong relationships with sell side analysts should be a critical element of any IR program. Learn ways to build rapport, optimize engagement, and support the analysts who influence investor perception of your company.

Make your investor relations calendar work harder. From planning milestones to creating new touchpoints, see how a strategic approach can strengthen engagement and visibility with life sciences investors.

Time to Refresh Your Corporate Deck? — Here’s How

Do you find yourself rushing to tell your whole story at conference meetings? Milestone Advisors shares some tips to sharpen your storytelling so that short meetings can lead to lasting investor interest.

The life sciences IPO window is beginning to open. Here’s how Milestone Advisors helps companies prepare S-1 filings that stand out and accelerate IPO readiness.

Why optimism is returning, but only disciplined stories are getting funded?

Innovative treatments are making meaningful strides against some of the largest unmet needs across medicine at the same time pharma has its greatest ever pressure to replenish pipelines with new products.